Extent of surgical procedure in triple negative breast carcinomas

Česká verze

Authors: J. Kotal ¹; V. Petrů ²; P. Kosáč ²; P. Vážan ³; M. Zábojníková ⁴; P. Jančík ²; M. Ratajský ²; K. Lajmar ²; B. Dudešek ²; J. Duben ²; P. Holík ⁵; J. Gatěk ^2,5
Authors place of work: Traumatologické oddělení, Krajská nemocnice Tomáše Bati, Zlín ¹; Chirurgické oddělení EUC kliniky, Zlín ²; Cytologická a bioptická laboratoř CGB, a. s., pracoviště Zlín ³; Onkologické oddělení, Krajská nemocnice Tomáše Bati Zlín ⁴; Univerzita Tomáše Bati ve Zlíně ⁵
Published in the journal: Rozhl. Chir., 2023, roč. 102, č. 4, s. 159-164.
Category: Původní práce
doi: https://doi.org/10.33699/PIS.2023.102.4.159–164

Summary

Introduction: Triple negative breast carcinomas (TNBC) account for approximately 15−20% of all breast carcinomas. This subtype is characterised by an unfavourable prognosis with early locoregional recurrence a metastases. Only few studies have focused on the impact of local surgery on the overall therapeutic outcome. However, decisions are difficult to make in the case of TNBC, and no particular molecular subtype or marker exists that would make the decision-making process easier. The aim of our retrospective study was to analyse the TNBC surgical management outcomes at EUC Clinic in Zlin.

Methods: 440 women with breast carcinoma were operated on at EUC Clinic from 2014 to 2016, including 29 patients with TNBC; bilateral carcinoma was present in one case. Neoadjuvant chemotherapy (NAC) was indicated in 6 cases. The tumour centre was marked with a clip. The extent of surgery depended on the residual size of the tumour. Sentinel lymph node biopsy was indicated in clinically negative lymph nodes; further management followed the Z0011 study if the biopsy was positive. Axillary lymph node dissection was performed after NAC. In all cases, surgery was followed by systemic chemotherapy, and by radiotherapy in the case of breast-conserving procedures.

Results: The group included 29 women and one patient with bilateral carcinoma, i.e. 30 cases of TNBC. Mean age was 57 years and median age was 55.5 years. Mean follow-up was 62.9 months, with the median of 69.9 month. NAC was indicated in 6 patients; complete pathological response was achieved in one case. NAC was followed by mastectomy in 5 cases including a bilateral procedure in one case, and by breast-conserving surgery in one case. Axillary dissection was performed in all cases. Breast-conserving surgery and sentinel node biopsy predominated in the group (16 cases). Local recurrence was observed in 4 cases, 2 times as an isolated local recurrence after one year and 2 times as part of generalization, always after mastectomy. Six patients died of generalized disease. No regional recurrence was observed.

Conclusion: TNBC is characterised by a worse prognosis and a higher rate of local recurrence. As confirmed by our study, the results of breast-conserving surgery can be comparable to those of radical procedures, and thus radical surgery should be indicated prudently.

Keywords:

local recurrence – triple negative carcinoma – breast-conserving surgery

Zdroje

1. Sharma S, Barry, Gallangher D, et al. An overview of triple negative breast cancer for surgical oncologists Surg Oncol. 2015 Sep;24(3):276−283. doi:10.1016/j.suronc. 2015.06.007.

2. Voduc K, Cheang M, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. Journal of Clinical Oncology 2010:(28):1684−1691.

3. Li X, Yang J, Peng L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple- negative breast cancer. Breast Cancer Res Treat. 2017 Jan;161(2):279−287. doi:10.1007/s10549-016-4059-6.

4. Li X, Yang J, Peng L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast cancer res treat. 2017;(161):279–287. doi:10.1007/s10549-016-4059-6.

5. Lin U, Vanderplas A, Melissa E, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer inthe National Comprehensive Cancer Network. Cancer 2012;(118):5463−5472. doi. org/10.1002/cncr.27581.

6. Fancelu A, Houssami N, Sanna V, et al. Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis. Br J Surg. 2021 Jul 23; 108(7):760−768. doi:10.1093/bjs/znab 145.

7. Guo L, Xie G, Wang R, et al. Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy? BMC Cancer 2021 Jun 19;21(1):717. doi:10.11.186/s12885-021- 08429-9.

8. Bernier J, Poortmans P. Surgery and radiation therapy of triple-negative breast cancers: From biology to clinics. The Breast 2016(28):148−155. doi:10.1016/j. breast.2016.05.014.

9. Golshan M, Loibl S, Wong S, et al. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer surgical results from the brighTNess randomized clinical trial. JAMA Surg. 2020;155(3):e195410. doi:10.1001/ jamasurg.2019.5410.

10. Morrow M. Surgery and prophylactic surgery in hereditary breast cancer. Breast 2022;(62):563−566. doi:10.1016/j.

11. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011;(305):569–575. doi:10.1001/ jama.2011.90.

12. Chen O, Wang X, Lin P, et al The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database. Oncotarget 2017 Jan 17;8(3):4773–4780. Published online 2016. doi:10.18632/oncotarget. 13976.

13. Yao Y, Chu Y, Xu B, et al Radiotherapy after surgery has significant survival benefits for patients with triple‐negative breast cancer Cancer Med. 2019 Feb;8(2):554– 563. doi:10.1002/cam4.1954.

14. Pan X, Qu S, Jiang P, et al. Triple negative breast cancer versus non-triple negative breast cancer treated with breast conservation surgery followed by radiotherapy: A systematic review and meta-analysis xin-bin. Breast Care 2015;(10):413−416. doi:10.1159/000441436.

15. Petrů V, Vážan P, Zábojníková M, et al. Chirurgická léčba karcinomu prsu po neoadjuvantní terapii. Rozhl Chir. 2020; 99(4)172−178. doi:10.33699/PIS.2020.99. 4.172–178.

16. Valachis A Mamounas E Mittendorf E, et al. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. Cancer 2018;(124):2923−2930. doi:10.1002/ cncr.31518.

17. Houssami N, Macaskill P, Minckwitz G, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy Eur J Cancer 201;48(18):3342−3354. doi:10.1016/j. ejca.2012.05.023. Epub 2012 Jul 3.

18. Karakatsanis A, Tasoulis A, Wärnberg G, et al. Meta-analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer. Br J Surg. 2018;105:469–481. doi:10.1002/ bjs.10807.

19. Boughey J, Suman V, PhD, Mittendorf E, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The American College of Surgeons Oncology Group (ACOSOG) Z1071 clinical trial. JAMA 2013 Oct 9; 310(14):1455–1461. doi:10.1001/jama.2013.278932.

20. Caudle A, Krishnamurthy S, Yang W, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: Implementation of targeted axillary dissection. J Clin Oncol. 2016 Apr 1;34(10):1072−1078.

21. Mamtani A, Barrio A King, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;(23):3467–3474. doi:10.1245/s10434-016-5246-8.

22. Gnant M, Thomssen CH, Harbeck N. St. Gallen/Vienna 2015: A brief summary of the consensus discussion. Breast Care 2015; Apr;10(2):124−130. doi:10.1159/00 0430488.

23. Weber W, Matrai Z, Hayoz S. Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101) Breast 2021;(60):98−110. doi:10.1016/j.breast.2021.09.004.